Moving up in this year's patent contentious rankings, Osler Hoskin & Harcourt has secured major wins for its generic pharmaceutical clients. "It has an exceptional team of patent litigators who understand the generic industry," said a client. "It really does have the strength and the team to deliver results." Even competitors couldn't withhold praise. "David Aitken, Marcus Klee, Brad White – all serious litigators," noted a peer. "They're winning cases; they're out there."
Hailed by a client as an exceptional team leader, J Bradley White is "a rare breed in that he can communicate well with business folks. And he'll be the bulldog we need him to be in the courtroom". Jonathan Cutler, added another, is "highly intelligent and very practical – a rare combination". Michael Fekete's transactional expertise and Jon Cotter's litigation skills were also praised: "They have stood out as particularly impressive in view of their consistent reliability, strong legal skills and trustworthiness," said a client.
Osler successfully represented ratiopharm, now Teva Canada, in separate proceedings that found Pfizer's patents on hypertension drugs Norvasc and Revatio invalid. As a result, generic versions of those drugs have entered the Canadian market.
The firm's trade mark and copyright practices remain highly ranked, with peers singling out Glen Bloom for his representation of artists and record companies. Bloom successfully represented Re:Sound before the Copyright Board in securing a decision that set royalties payable to the music licensing company by commercial radio stations.